Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Endometrial Adenocarcinoma 1Bilateral Breast Carcinoma 1

Interventions

Specimen Handling 191Magnetic Resonance Spectroscopy 141Biopsy 102pembrolizumab 82Carboplatin 76Cisplatin 68Nivolumab 62Radiotherapy 51Paclitaxel 51Gemcitabine 50Cyclophosphamide 48Dexamethasone 46durvalumab 39Radiation 39atezolizumab 36Pemetrexed 36olaparib 34Rituximab 34venetoclax 33Etoposide 33Doxorubicin 32Lenalidomide 31X-Rays 30Prednisone 30Bevacizumab 30Docetaxel 28Disulfides 28Immunoglobulin G 27Vincristine 26Ipilimumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Epothilones × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡